These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24276238)

  • 21. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
    Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
    Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
    Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
    Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.
    Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K
    J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
    Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
    Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
    Wu C; Wang S; Xu C; Tyler A; Li X; Andersson C; Oji Y; Sugiyama H; Chen Y; Li A
    Cell Physiol Biochem; 2015; 35(2):647-62. PubMed ID: 25613309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.
    Baumgart A; Mazur PK; Anton M; Rudelius M; Schwamborn K; Feuchtinger A; Behnke K; Walch A; Braren R; Peschel C; Duyster J; Siveke JT; Dechow T
    Oncogene; 2015 Jan; 34(5):578-88. PubMed ID: 24509876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
    Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
    Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PKC
    Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
    Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
    Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
    Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
    Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
    Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERβ regulates NSCLC phenotypes by controlling oncogenic RAS signaling.
    Nikolos F; Thomas C; Rajapaksa G; Bado I; Gustafsson JÅ
    Mol Cancer Res; 2014 Jun; 12(6):843-54. PubMed ID: 24618619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
    Cho HC; Lai CY; Shao LE; Yu J
    Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.
    Tessema M; Yingling CM; Snider AM; Do K; Juri DE; Picchi MA; Zhang X; Liu Y; Leng S; Tellez CS; Belinsky SA
    J Thorac Oncol; 2014 Jun; 9(6):784-93. PubMed ID: 24807155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
    Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
    Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
    Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
    Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wildtype Kras2 can inhibit lung carcinogenesis in mice.
    Zhang Z; Wang Y; Vikis HG; Johnson L; Liu G; Li J; Anderson MW; Sills RC; Hong HL; Devereux TR; Jacks T; Guan KL; You M
    Nat Genet; 2001 Sep; 29(1):25-33. PubMed ID: 11528387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
    Zhou X; Updegraff BL; Guo Y; Peyton M; Girard L; Larsen JE; Xie XJ; Zhou Y; Hwang TH; Xie Y; Rodriguez-Canales J; Villalobos P; Behrens C; Wistuba II; Minna JD; O'Donnell KA
    Cancer Res; 2017 Jan; 77(1):187-197. PubMed ID: 27821484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ETS1 regulates Twist1 transcription in a Kras
    Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
    Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
    Moran DM; Trusk PB; Pry K; Paz K; Sidransky D; Bacus SS
    Mol Cancer Ther; 2014 Jun; 13(6):1611-24. PubMed ID: 24688052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.